Chronic lung disease-associated PH: PAH-approved drugs and established universal healthcare insurance in Japan

Respir Investig. 2020 Jul;58(4):230-231. doi: 10.1016/j.resinv.2020.03.002. Epub 2020 Apr 9.

Author

Seiichiro Sakao¹

Affiliation

¹ Department of Respirology (B2), Graduate School of Medicine, Chiba University, 1-8-1 Inohana, Chuo-ku, Chiba, 260-8670, Japan. Electronic address: sakaos@faculty.chiba-u.jp.

PMID: 32279941
DOI: 10.1016/j.resinv.2020.03.002

No abstract available

Keywords: Chronic lung disease; Chronic obstructive pulmonary disease; Idiopathic pulmonary fibrosis; Pulmonary hypertension.

Publication types

Editorial

MeSH terms

Bosentan / adverse effects
Bosentan / therapeutic use*
Humans
Hypertension, Pulmonary / drug therapy*
Hypertension, Pulmonary / epidemiology
Hypertension, Pulmonary / etiology*
Idiopathic Pulmonary Fibrosis / complications*
Insurance Coverage*
Japan
Phenylpropionates / adverse effects
Phenylpropionates / therapeutic use*
Prevalence
Prognosis
Pulmonary Disease, Chronic Obstructive / complications*
Pyrazoles / adverse effects
Pyrazoles / therapeutic use*
Pyridazines / adverse effects
Pyridazines / therapeutic use*
Pyrimidines / adverse effects
Pyrimidines / therapeutic use*
Sildenafil Citrate / adverse effects
Sildenafil Citrate / therapeutic use*
Sulfonamides / adverse effects
Sulfonamides / therapeutic use*
Treatment Outcome
Universal Health Insurance*

Substances

Phenylpropionates
Pyrazoles
Pyridazines
Pyrimidines
Sulfonamides
Sildenafil Citrate
ambrisentan
Bosentan
riociguat
macitentan